中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

83 records (took 0.074 seconds)

    METHOD FOR REDUCING IMMUNOGENICITY OF RNA
    71.
    发明公开
    METHOD FOR REDUCING IMMUNOGENICITY OF RNA 审中-公开

    公开(公告)号：US20240084288A1

    公开(公告)日：2024-03-14

    申请号：US18515879

    申请日：2023-11-21

    Applicant: BioNTech SE

    Inventor： Katalin Kariko ,  Ugur Sahin

    IPC: C12N15/10 ,  C07K14/505 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

    CPC classification number: C12N15/102 ,  C07K14/505 ,  C12N15/10 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

    Abstract: The present invention relates to RNA therapy and, in particular, decreasing immunogenicity of RNA. Specifically, the present invention provides methods for decreasing immunogenicity of RNA, said methods comprising modifying the nucleotide sequence of the RNA by reducing the uridine (U) content, wherein said reduction of the U content comprises an elimination of U nucleosides from the nucleotide sequence of the RNA and/or a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA. Using RNA having decreased immunogenicity allows administration of RNA as a drug to a subject, e.g. in order to obtain expression of a pharmaceutically active peptide or protein, without eliciting an immune response which would interfere with therapeutic effectiveness of the RNA or induce adverse effects in the subject.

    Method for reducing immunogenicity of RNA
    74.
    发明授权
    Method for reducing immunogenicity of RNA 有权

    公开(公告)号：US11873478B2

    公开(公告)日：2024-01-16

    申请号：US17012599

    申请日：2020-09-04

    Applicant: BioNTech SE

    Inventor： Katalin Kariko ,  Ugur Sahin

    IPC: C12N15/10 ,  C12N15/67 ,  C12P19/34 ,  C12N15/88 ,  C07K14/505

    CPC classification number: C12N15/102 ,  C07K14/505 ,  C12N15/10 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

    Abstract: The present invention relates to RNA therapy and, in particular, decreasing immunogenicity of RNA. Specifically, the present invention provides methods for decreasing immunogenicity of RNA, said methods comprising modifying the nucleotide sequence of the RNA by reducing the uridine (U) content, wherein said reduction of the U content comprises an elimination of U nucleosides from the nucleotide sequence of the RNA and/or a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA. Using RNA having decreased immunogenicity allows administration of RNA as a drug to a subject, e.g. in order to obtain expression of a pharmaceutically active peptide or protein, without eliciting an immune response which would interfere with therapeutic effectiveness of the RNA or induce adverse effects in the subject.

    BINDING AGENTS FOR CORONAVIRUS S PROTEIN
    78.
    发明公开
    BINDING AGENTS FOR CORONAVIRUS S PROTEIN 审中-公开

    公开(公告)号：US20230287088A1

    公开(公告)日：2023-09-14

    申请号：US18019787

    申请日：2021-07-29

    Applicant: BIONTECH SE

    Inventor： Karsten Beckmann ,  Anna Carle ,  Sandra Prassl ,  Claudia Paulmann ,  Christiane Stadler ,  Georg Falck ,  Leyla Fischer ,  Alexander Muik ,  Ugur Sahin ,  Caroline Scharf

    IPC: C07K16/10 ,  A61P31/14

    CPC classification number: C07K16/10 ,  A61P31/14 ,  C07K2317/31 ,  C07K2317/92

    Abstract: The present disclosure relates to a binding agent comprising a first and a second binding domain, wherein the first binding domain is capable of binding to a coronavirus spike protein (S protein) and the second binding domain is capable of binding to the coronavirus S protein, and wherein the first and second binding domains bind to different epitopes of the coronavirus S protein. Moreover, the disclosure relates to an antibody capable of binding to a coronavirus spike protein (S protein). The disclosure also relates to a nucleic acid such as RNA encoding the binding agent, in particular antibody, disclosed herein and a host cell transformed or transfected with said nucleic acid. Furthermore, the disclosure relates to a medical use of said binding agent, antibody, or nucleic acid. The agents and medical uses described herein are, in particular, useful for the prevention or treatment of coronavirus infection in a subject.

Patent Agency Ranking